Abstract | PURPOSE: PATIENTS AND METHODS: We analyzed a population-based cohort of 74 children with relapsed ALCL after Berlin-Frankfurt-Muenster-type first-line therapy between April 1990 and December 2003. The recommended salvage strategy was reinduction chemotherapy followed by autologous hematopoietic stem-cell transplantation (SCT). RESULTS: With a median follow-up time of 8.4 years (range, 4.5 to 16.4 years), the 5-year overall survival (OS) rate after first relapse was 57% ± 6%. Survival correlated with time of relapse and clinically advanced dissemination. Five-year OS of 16 patients who experienced progression during first-line therapy was 25% ± 11% compared with 66% ± 6% for 58 patients with a later relapse (P = .002). Five-year OS of 11 patients with bone marrow or CNS involvement was 27% ± 13% compared with 62% ± 6% for 63 patients without involvement (P = .001). Five-year event-free survival (EFS) and OS of 39 children who received the recommended autologous SCT were 59% ± 8% and 77% ± 7%, respectively. EFS after autologous SCT was significantly associated with time to relapse (progression: n = 3; EFS, 0; later relapse: n = 36; EFS, 64% ± 8%; P = .014) and CD3 expression (CD3 negative: n = 25; EFS, 72% ± 9%; CD3 positive: n = 11; EFS, 18% ± 12%; P < .001), but not with site of relapse, conditioning regimen, or graft manipulation. No relapses occurred among 10 patients with relapsed CD3-positive ALCL treated with allogeneic SCT. CONCLUSION: Reinduction chemotherapy followed by autologous SCT proved feasible and efficacious for patients with a first relapse of CD3-negative ALCL after first-line therapy. Patients with progression during first-line therapy or relapsed CD3-positive ALCL may benefit from allogeneic SCT.
|
Authors | Willi Woessmann, Martin Zimmermann, Meike Lenhard, Birgit Burkhardt, Claudia Rossig, Bernhard Kremens, Peter Lang, Andishe Attarbaschi, Georg Mann, Ilske Oschlies, Wolfram Klapper, Alfred Reiter |
Journal | Journal of clinical oncology : official journal of the American Society of Clinical Oncology
(J Clin Oncol)
Vol. 29
Issue 22
Pg. 3065-71
(Aug 01 2011)
ISSN: 1527-7755 [Electronic] United States |
PMID | 21709186
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Topics |
- Adolescent
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Child
- Child, Preschool
- Disease-Free Survival
- Feasibility Studies
- Female
- Hematopoietic Stem Cell Transplantation
- Humans
- Immunohistochemistry
- Immunophenotyping
- Lymphoma, Large-Cell, Anaplastic
(drug therapy, surgery)
- Male
- Predictive Value of Tests
- Prognosis
- Recurrence
- Remission Induction
- Risk Assessment
- Risk Factors
- Salvage Therapy
(methods)
- Transplantation, Autologous
- Treatment Outcome
|